{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:11:29Z","timestamp":1776244289357,"version":"3.50.1"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004912","name":"Sichuan University","doi-asserted-by":"publisher","award":["ZYGD20008"],"award-info":[{"award-number":["ZYGD20008"]}],"id":[{"id":"10.13039\/501100004912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013365","name":"West China Hospital of Sichuan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013365","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017520","name":"Chengdu Medical College","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017520","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1303200"],"award-info":[{"award-number":["2022YFA1303200"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117755","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T19:05:38Z","timestamp":1747163138000},"page":"117755","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Structure-directing optimization of N-(2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)benzamide derivatives as selective receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer therapy"],"prefix":"10.1016","volume":"294","author":[{"given":"Qingquan","family":"Zheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hulin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongdong","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingyang","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Ming","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchen","family":"Pu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Min","family":"Ai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianhua","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1181-3467","authenticated-orcid":false,"given":"Yong","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.117755_bib1","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrc3277","article-title":"Spatial regulation of receptor tyrosine kinases in development and cancer","volume":"12","author":"Casaletto","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.117755_bib2","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s13238-014-0059-7","article-title":"ROR1, an embryonic protein with an emerging role in cancer biology","volume":"5","author":"Borcherding","year":"2014","journal-title":"Protein Cell"},{"key":"10.1016\/j.ejmech.2025.117755_bib3","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 protein expression in human cancer and normal tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.117755_bib4","article-title":"Tyrosine kinase ROR1 as a target for anti-cancer therapies","volume":"11","author":"Zhao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.117755_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2023.110588","article-title":"The signaling pathways activated by ROR1 in cancer","volume":"104","author":"Quezada","year":"2023","journal-title":"Cell. Signal."},{"key":"10.1016\/j.ejmech.2025.117755_bib6","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1038\/s41375-022-01543-y","article-title":"High expression level of ROR1 and ROR1-signaling associates with venetoclax resistance in chronic lymphocytic leukemia","volume":"36","author":"Ghia","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117755_bib7","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/s41375-020-01055-7","article-title":"Wnt5a enhances proliferation of chronic lymphocytic leukemia and ERK1\/2 phosphorylation via a ROR1\/DOCK2-dependent mechanism","volume":"35","author":"Hasan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117755_bib8","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1182\/bloodadvances.2017010215","article-title":"Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma","volume":"1","author":"Karvonen","year":"2017","journal-title":"Blood Adv."},{"key":"10.1016\/j.ejmech.2025.117755_bib9","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/biof.1498","article-title":"ROR1 associates unfavorable prognosis and promotes lymphoma growth in DLBCL by affecting PI3K\/Akt\/mTOR signaling pathway","volume":"45","author":"Mao","year":"2019","journal-title":"Biofactors"},{"key":"10.1016\/j.ejmech.2025.117755_bib10","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.4049\/jimmunol.1801327","article-title":"Cutting edge: ROR1\/CD19 receptor complex promotes growth of mantle cell lymphoma cells independently of the B cell Receptor-BTK signaling pathway","volume":"203","author":"Zhang","year":"2019","journal-title":"J. Immunol."},{"key":"10.1016\/j.ejmech.2025.117755_bib11","article-title":"ROR1 is a novel prognostic biomarker in patients with lung adenocarcinoma","volume":"6","author":"Zheng","year":"2016","journal-title":"Sci Rep-Uk"},{"key":"10.1016\/j.ejmech.2025.117755_bib12","doi-asserted-by":"crossref","first-page":"32864","DOI":"10.18632\/oncotarget.15860","article-title":"ROR1 expression as a biomarker for predicting prognosis in patients with colorectal cancer","volume":"8","author":"Zhou","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.117755_bib13","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2019.05.016","article-title":"Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer","volume":"458","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.117755_bib14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12943-024-02075-y","article-title":"Novel humanized monoclonal antibodies against ROR1 for cancer therapy","volume":"23","author":"Wei","year":"2024","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ejmech.2025.117755_bib15","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1073\/pnas.1816262116","article-title":"Inhibition of chemotherapy resistant breast cancer stem cells by a ROR1 specific antibody","volume":"116","author":"Zhang","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ejmech.2025.117755_bib16","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3390\/pharmaceutics14040837","article-title":"The Anti-ROR1 monoclonal antibody zilovertamab inhibits the proliferation of ovarian and endometrial cancer cells","volume":"14","author":"Liu","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.117755_bib17","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1038\/leu.2016.368","article-title":"Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib","volume":"31","author":"Yu","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117755_bib18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS1108","article-title":"NBE-002: a novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors-A phase 1\/2 clinical trial","volume":"39","author":"Tolcher","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"Supplement 1","key":"10.1016\/j.ejmech.2025.117755_bib19","first-page":"33","article-title":"Targeting ROR1 using the antibody drug conjugate Vls-101 in aggressive mantle cell lymphoma","volume":"136","author":"Jiang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117755_bib20","doi-asserted-by":"crossref","first-page":"3365","DOI":"10.1182\/blood.2020008404","article-title":"ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in richter syndrome patient-derived xenograft mouse models","volume":"137","author":"Vaisitti","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117755_bib21","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79","article-title":"Phase I study of immunotherapy for advanced ROR1+malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells","volume":"36","author":"Specht","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117755_bib22","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ccell.2020.11.005","article-title":"Immunogenic chemotherapy enhances recruitment of CAR-T cells to lung tumors and improves antitumor efficacy when combined with checkpoint blockade","volume":"39","author":"Srivastava","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117755_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198038","article-title":"A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib","volume":"13","author":"Daneshmanesh","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117755_bib24","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.3390\/pharmaceutics14102238","article-title":"A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of mantle cell lymphoma (MCL) cells","volume":"14","author":"Ghaderi","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2025.117755_bib25","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7592","article-title":"Open-label, active-control, phase 2\/3 study of zilovertamab vedotin plus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117755_bib26","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS7595","article-title":"waveLINE-006: a phase 2 study of the safety and efficacy of zilovertamab vedotin as monotherapy or in combination in patients (pts) with aggressive and indolent B-cell malignancies","volume":"41","author":"Zinzani","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117755_bib27","doi-asserted-by":"crossref","first-page":"7535","DOI":"10.1200\/JCO.2022.40.16_suppl.7535","article-title":"First-in-human phase I study of a ROR1-targeting bispecific T-cell engager (NVG-111) shows evidence of efficacy in patients with relapsed\/refractory CLL and MCL","volume":"40","author":"Jasani","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117755_bib28","doi-asserted-by":"crossref","first-page":"TPS79","DOI":"10.1200\/JCO.2018.36.5_suppl.TPS79","article-title":"Phase I study of immunotherapy for advanced ROR1+malignancies with autologous ROR1-specific chimeric antigen receptor-modified (CAR)-T cells","volume":"36","author":"Specht","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.117755_bib29","doi-asserted-by":"crossref","first-page":"10967","DOI":"10.1021\/acs.jmedchem.4c00511","article-title":"Development of peptide paratope mimics derived from the Anti-ROR1 antibody and long-acting peptide-drug conjugates for targeted cancer therapy","volume":"67","author":"Zhang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117755_bib30","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117755_bib31","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms10060","article-title":"ROR1 sustains caveolae and survival signalling as a scaffold of cavin-1 and caveolin-1","volume":"7","author":"Yamaguchi","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.117755_bib32","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/s41375-018-0113-1","article-title":"First-in-class oral small molecule inhibitor of the tyrosine kinase ROR1 (KAN0439834) induced significant apoptosis of chronic lymphocytic leukemia cells","volume":"32","author":"Hojjat-Farsangi","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117755_bib33","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126801","article-title":"Diffuse large B cell lymphoma (DLBCL) expresses ROR1 and a ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of tumor cells","volume":"134","author":"Hojjat-Farsangi","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117755_bib34","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood.V126.23.2912.2912","article-title":"First-in-Class ROR1 small molecule inhibitor (KAN0439834) downregulated wnt-canonical and non-canonical signaling pathways and induced apoptosis of CLL cells","volume":"126","author":"Hojjat-Farsangi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ejmech.2025.117755_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106484","article-title":"Design, synthesis, and biological evaluation of 6-(imidazo[1,2-a] pyridin-6-yl) quinazolin-4(3H)-one derivatives as potent anticancer agents by dual targeting Aurora kinase and ROR1","volume":"135","author":"Fan","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.117755_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0217789","article-title":"Strictinin, a novel ROR1-inhibitor, represses triple negative breast cancer survival and migration via modulation of PI3K\/AKT\/GSK3ss activity","volume":"14","author":"Fultang","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.117755_bib37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.canlet.2019.05.016","article-title":"Novel ROR1 inhibitor ARI-1 suppresses the development of non-small cell lung cancer","volume":"458","author":"Liu","year":"2019","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.117755_bib38","doi-asserted-by":"crossref","first-page":"10655","DOI":"10.1021\/acs.jmedchem.4c00175","article-title":"Discovery of novel receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer treatment","volume":"67","author":"Luo","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117755_bib39","first-page":"683","article-title":"Role and significance of c-KIT receptor tyrosine kinase in cancer: a review","volume":"22","author":"Sheikh","year":"2022","journal-title":"Biomol. Biomed."},{"key":"10.1016\/j.ejmech.2025.117755_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.109538","article-title":"The molecular signature of BCR::ABL(P210) and BCR::ABL(T315I) in a Drosophila melanogaster chronic myeloid leukemia model","volume":"27","author":"Baassiri","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ejmech.2025.117755_bib41","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1038\/leu.2017.133","article-title":"Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells","volume":"31","author":"Hasan","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ejmech.2025.117755_bib42","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41523-019-0131-9","article-title":"Wnt5a induces ROR1 to recruit cortactin to promote breast-cancer migration and metastasis","volume":"5","author":"Hasan","year":"2019","journal-title":"Npj Breast Cancer"},{"key":"10.1016\/j.ejmech.2025.117755_bib43","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.molcel.2020.06.018","article-title":"Structural insights into pseudokinase domains of receptor tyrosine kinases","volume":"79","author":"Sheetz","year":"2020","journal-title":"Mol. Cell"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005203?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425005203?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:12:50Z","timestamp":1765602770000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425005203"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":43,"alternative-id":["S0223523425005203"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117755","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Structure-directing optimization of N-(2,3-dihydrobenzo[b] [1,4]dioxin-6-yl)benzamide derivatives as selective receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitors for cancer therapy","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117755","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117755"}}